Status:
UNKNOWN
ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT
Lead Sponsor:
Peking University
Conditions:
Glomerulonephritis, IGA
Eligibility:
All Genders
16-65 years
Phase:
NA
Brief Summary
IgA nephropathy( IgAN) is the most common primary glomerulonephritis worldwide. Since the etiology of the disease is not clearly understood, no specific therapeutic strategies was defined for IgAN. Bo...
Detailed Description
IgA nephropathy( IgAN) is the most common primary glomerulonephritis worldwide. Since the etiology of the disease is not clearly understood, no specific therapeutic strategies was defined for IgAN. In...
Eligibility Criteria
Inclusion
- underwent renal biopsy within 1 year before start fo trial;
- 24 hour urinary protein excretion ranged between 1 to 7 g/d;
- eGFR, evaluated by MDRD formula, should be higher than 30 ml/min
Exclusion
- crescentic glomerulonephritis;
- steroid therapy subjected within 1 year before trial;
- malignant hypertension(DBP\> 130 mmHg and/or SBP\> 220mmHg), resistant to anti-hypertensive agents;
- urinary protein excretion decrease below 1 g/l after run-in period;
- Myocardial infarction or cerebrovascular accident in 6 months preceding the trial;
- renovascular disease;
- diabetes mellitus;
- Malignancy, severe liver disease, refractory infection;
- peptic ulcer in active disease phase;
- pregnancy;
- other contraindication to the use of ACEi/ ARB or corticosteroid;
- alcohol abuse or drug addiction
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
End Date :
June 1 2007
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00378443
Start Date
January 1 2006
End Date
June 1 2007
Last Update
September 22 2006
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.